<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C49C66E3-8EF1-43E8-82A1-7A8347F84C2B"><gtr:id>C49C66E3-8EF1-43E8-82A1-7A8347F84C2B</gtr:id><gtr:name>Sentinel Oncology Limited</gtr:name><gtr:address><gtr:line1>SUITE 52 23 SCIENCE PARK , MILTON ROAD</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB4 0EY</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C49C66E3-8EF1-43E8-82A1-7A8347F84C2B" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>C49C66E3-8EF1-43E8-82A1-7A8347F84C2B</gtr:id><gtr:name>Sentinel Oncology Limited</gtr:name><gtr:address><gtr:line1>SUITE 52 23 SCIENCE PARK , MILTON ROAD</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB4 0EY</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>100000.0</gtr:offerGrant><gtr:projectCost>178794.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=710121"><gtr:id>263FDA7E-716F-4305-B03C-4F967B5A3B19</gtr:id><gtr:title>Sentinel Oncology ? Optimisation of Chk1 inhibitors for treatment of Glioblastoma</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Concept</gtr:grantCategory><gtr:grantReference>710121</gtr:grantReference><gtr:abstractText>Glioblastoma is a cancer of the brain which, although relatively rare, has a very poor survival
rate. It is particularly deadly in young patients and overall survival for all patient groups over
5 years is less than 3%. One reason for the poor prognosis and survival rate is that the
available treatments have progressed very little over the past 30 years, with surgery followed
by radiotherapy being the only real option. Glioblastoma tumours rapidly develop resistance
to treatment and the aim of this project will be to develop a drug with the ability to reverse
that resistance and make the existing therapies effective once more.</gtr:abstractText><gtr:fund><gtr:end>2012-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2012-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>100000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">710121</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>